無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

アトピー性皮膚炎:パイプライン分析

Atopic Dermatitis (Atopic Eczema) - Pipeline Review, H2 2018

発行 Global Markets Direct 商品コード 232797
出版日 ページ情報 英文 440 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.94円で換算しております。
Back to Top
アトピー性皮膚炎:パイプライン分析 Atopic Dermatitis (Atopic Eczema) - Pipeline Review, H2 2018
出版日: 2018年08月28日 ページ情報: 英文 440 Pages
概要

アトピー性皮膚炎は皮膚がかゆくなる炎症で、慢性的に症状が長引き、喘息や花粉症を伴うこともあります。 症侯は、赤から茶色がかった灰色の斑点、痒みがあり、特に夜はひどくなります。小さく隆起したコブができ、掻くと体液が漏出してかさぶたになる、肥厚性の鱗状の皮膚、掻くことで爛れて敏感になった皮膚などが挙げられます。

当レポートでは、アトピー性皮膚炎の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲
  • アトピー性皮膚炎 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • Abeome Corporation
  • Accolade Pharmaceuticals, LLC
  • AlbireoPharma
  • Almirall, S.A.
  • Amgen Inc.
  • Amorepacific Corporation
  • Anacor Pharmaceuticals, Inc.
  • AnaMar AB
  • AnaptysBio, Inc.
  • AnGes MG, Inc.
  • Aquinox Pharmaceuticals Inc.
  • arGEN-X BV
  • Blueberry Therapeutics Ltd
  • Brickell Biotech, Inc.
  • Celgene Corporation
  • ChemoCentryx, Inc.
  • ChironWells GmbH
  • 中外製薬
  • Creabilis SA
  • Delenex Therapeutics AG
  • Dermira Inc.
  • Dr. August Wolff GmbH & Co. KG Arzneimittle
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Foamix Pharmaceuticals Ltd.
  • Fountain Biopharma Inc.
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd.
  • Grupo Ferrer Internacional, S.A.
  • Han Wha Pharma Co., Ltd.
  • HanAll Biopharma Co., Ltd.
  • Herantis Pharma Plc
  • Immune Pharmaceuticals Inc.
  • Inflamalps SA
  • 日本たばこ産業
  • Johnson & Johnson
  • Kineta, Inc.
  • LegoChem Biosciences, Inc
  • LEO Pharma A/S
  • Madam Therapeutics B.V.
  • MedImmune, LLC
  • NeoPharm Co., Ltd.
  • Novan, Inc.
  • Novartis AG
  • Orbis Biosciences, Inc.
  • 大塚ホールディングス
  • Oxagen Limited
  • Pfizer Inc.
  • Pharis Biotec GmbH
  • Pharmedartis GmbH
  • Provectus Biopharmaceuticals, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Signum Dermalogix, Inc
  • Spherium Biomed S.L.
  • sterna biologicals Gmbh & Co KG
  • Sucampo Pharmaceuticals, Inc.
  • Sun Pharma Advanced Research Company Ltd.
  • SWITCH Biotech LLC
  • 武田薬品工業
  • Thesan Pharmaceuticals, Inc.
  • Valeant Pharmaceuticals International, Inc.
  • Vicore Pharma AB
  • Vitae Pharmaceuticals, Inc.
  • VivaCell Biotechnology Espana S.L.
  • Xencor, Inc.
  • Ziarco Pharma Ltd

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • A-3914
  • A-5425
  • AKP-11
  • ALX-101
  • AM-1030
  • AN-4161
  • ANB-020
  • apremilast
  • アトピー性皮膚炎向けガレクチン-3阻害アプトマー
  • AQX-1125
  • ARGX-112
  • ARN-077
  • baricitinib
  • BB-2702
  • BBI-2000
  • BBI-5000
  • bertilimumab
  • アトピー性皮膚炎・皮膚炎向け生物製剤
  • C-21
  • CBP-174
  • CBP-201
  • CCX-6239
  • CDE-001
  • Cis-Urocanic Acid
  • CNTO-7160
  • コバマミド
  • crisaborole
  • CT-101
  • CT-1x1
  • CT-1x2
  • CT-1x3
  • CT-327
  • CT-340
  • シクロスポリン
  • dalazatide
  • DMT-210
  • DRM-02
  • アトピー性皮膚炎治療薬
  • アトピー性皮膚炎向け TNFR-1拮抗薬
  • デュピルマブ
  • FB-825
  • fevipiprant
  • FIB-116
  • Furestem-AD
  • GBR-830
  • Histimex
  • HS-378
  • JTE-052
  • KPI-150
  • LCB-030110
  • lebrikizumab
  • LEKTI-6
  • LEO-32731
  • LEO-39652
  • mepolizumab
  • MLR-1130
  • mometasone furoate
  • 喘息・線維症・アトピー性皮膚炎向け IL-25阻害モノクローナル抗体
  • アトピー性皮膚炎向け IL-4/IL-13阻害モノクローナル抗体
  • 炎症性大腸炎・ アトピー性皮膚炎・大腸癌向け Th22細胞/IL-22経路標的モノクローナル抗体
  • N-oleoylethanolamine
  • nemolizumab
  • NPH-12
  • OC-000459
  • OC-2417
  • octenidine hydrochloride
  • OLX-103
  • omiganan pentahydrochloride
  • OPA-15406
  • P-10
  • PAC-14028
  • PDI-192
  • アトピー性皮膚炎向け CX3CR1拮抗ペプチド
  • アトピー性皮膚炎向け TNFR-1拮抗ペプチド
  • PH-10
  • PL-601
  • PMA-101R
  • PMA-201
  • PMA-411R
  • prednisone
  • PZ-235
  • Q-301
  • Qi-507
  • roflumilast
  • RTU-1096
  • RVT-501
  • S-414114
  • SB-011
  • SB-414
  • SIG-1311
  • SIG-1322
  • アトピー性皮膚炎向け S1PR1調整薬
  • アトピー性皮膚炎向け向け小分子
  • SP-14019
  • SUN-0597
  • SWT-01113
  • SWT-05141
  • 免疫学・皮膚疾患・遺伝性疾患向けカリクレイン阻害合成ペプチド
  • tacrolimus
  • tezepelumab
  • tofacitinib
  • tralokinumab
  • ustekinumab
  • VTP-38543
  • WBI-1001
  • WOL-071007
  • XmAb-7195
  • YJC-10592
  • Zafi-1
  • ZPL-3893787
  • ZPL-5212372

最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

図表

List of Tables

  • Number of Products under Development for Atopic Dermatitis (Atopic Eczema), H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Stage and Target, H2 2018
  • Number of Products by Stage and Mechanism of Action, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by AbbVie Inc, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Abeome Corp, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Accolade Pharmaceuticals LLC, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Aclaris Therapeutics Inc, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Allergan Plc, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Almirall SA, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Amgen Inc, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Amorepacific Corp, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by AnaptysBio Inc, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by AntibioTx AS, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Asana BioSciences LLC, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Bausch Health Companies Inc, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Bioleaders Corp, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Blueberry Therapeutics Ltd, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Celgene Corp, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by ChironWells GmbH, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Clevexel Pharma SAS, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Cutanea Life Sciences Inc, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Dermala Inc, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by DURECT Corp, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Eli Lilly and Co, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Evelo Biosciences Inc, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Evotec AG, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Fountain Biopharma Inc, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Galapagos NV, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Galderma SA, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Galectin Therapeutics Inc, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by GlaxoSmithKline Plc, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Glenmark Pharmaceuticals Ltd, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Golden Biotechnology Corp, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Han Wha Pharma Co Ltd, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Heptares Therapeutics Ltd, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by iCo Therapeutics Inc, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Immune Pharmaceuticals Inc, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Incyte Corp, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Inflamalps SA, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Innovation Pharmaceuticals Inc, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Japan Tobacco Inc, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by JW Pharmaceutical Corp, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Kang Stem Biotech Co Ltd, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Kv1.3 Therapeutics, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Lead Pharma Holding BV, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by LEO Pharma A/S, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Madam Therapeutics BV, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Medicenna Therapeutics Corp, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by MedImmune LLC, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by NeoPharm Co Ltd, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by NeuroCycle Therapeutics GmbH, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Novan Inc, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Novartis AG, H2 2018
  • Atopic Dermatitis (Atopic Eczema) - Pipeline by Nuevolution AB, H2 2018

List of Figures

  • Number of Products under Development for Atopic Dermatitis (Atopic Eczema), H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Top 10 Targets, H2 2018
  • Number of Products by Stage and Top 10 Targets, H2 2018
  • Number of Products by Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Top 10 Routes of Administration, H2 2018
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2018
  • Number of Products by Top 10 Molecule Types, H2 2018
  • Number of Products by Stage and Top 10 Molecule Types, H2 2018
目次
Product Code: GMDHC10740IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atopic Dermatitis (Atopic Eczema) - Pipeline Review, H2 2018, provides an overview of the Atopic Dermatitis (Atopic Eczema) (Dermatology) pipeline landscape.

Atopic dermatitis is an itchy inflammation of skin. Signs and symptoms of atopic dermatitis include red to brownish-gray colored patches, itching, which may be severe, especially at night, small, raised bumps, which may leak fluid and crust over when scratched, thickened, cracked or scaly skin and raw, sensitive skin from scratching. Risk factors include family history of eczema, allergies, hay fever or asthma and gender.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atopic Dermatitis (Atopic Eczema) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Atopic Dermatitis (Atopic Eczema) (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atopic Dermatitis (Atopic Eczema) (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Atopic Dermatitis (Atopic Eczema) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 10, 42, 20, 1, 46, 14 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 4 and 2 molecules, respectively.

Atopic Dermatitis (Atopic Eczema) (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Atopic Dermatitis (Atopic Eczema) (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Atopic Dermatitis (Atopic Eczema) (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Atopic Dermatitis (Atopic Eczema) (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Atopic Dermatitis (Atopic Eczema) (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Atopic Dermatitis (Atopic Eczema) (Dermatology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Atopic Dermatitis (Atopic Eczema) (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Atopic Dermatitis (Atopic Eczema) (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Atopic Dermatitis (Atopic Eczema) - Overview
  • Atopic Dermatitis (Atopic Eczema) - Therapeutics Development
  • Atopic Dermatitis (Atopic Eczema) - Therapeutics Assessment
  • Atopic Dermatitis (Atopic Eczema) - Companies Involved in Therapeutics Development
  • Atopic Dermatitis (Atopic Eczema) - Drug Profiles
  • Atopic Dermatitis (Atopic Eczema) - Dormant Projects
  • Atopic Dermatitis (Atopic Eczema) - Discontinued Products
  • Atopic Dermatitis (Atopic Eczema) - Product Development Milestones
  • Appendix
Back to Top